Shuya Kandori

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

Andrea Necchi, M. Roumiguié, Ashish M. Kamat et al. · The Lancet Oncology · 2024 · 85 citations · Full text

Medicine, Oncology, Pharmacology +14

Real-Time Balloon Inflation Elastography for Prostate Cancer Detection and Initial Evaluation of Clinicopathologic Analysis

Masakazu Tsutsumi, Tomoaki Miyagawa, Takeshi Matsumura et al. · American Journal of Roentgenology · 2010 · 62 citations

Medicine, Surgery, Urology +17

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama et al. · The Lancet · 2025 · 47 citations · Full text

Medicine, Oncology, Urology +13

ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma

Ken Tanaka, Shuya Kandori, Shotaro Sakka et al. · Oncology Reports · 2021 · 42 citations · Full text

Medicine, Nephrology, Metastasis +14

Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies

Akira Joraku, Kentaro Hatano, Koji Kawai et al. · Annals of Nuclear Medicine · 2018 · 33 citations

Medicine, Nuclear Medicine, Radiology +14